In conclusion, we demonstrate that sGC stimulation by riociguat ameliorates portal hypertension, reduces liver fibrosis and inhibits hepatic necroinflammation – especially in cholestatic cirrhosis. Here, SGCB is linked to primary biliary cholangitis.